View Older Stories View More Recent Stories

Sep 15, 2022 04:02PM Syros Pharmaceuticals (SYRS) and Tyme Technologies (TYME) Shareholders Approve Merger
Sep 15, 2022 04:01PM Syros and Tyme Technologies Announce Stockholder Approval of Merger
Sep 13, 2022 04:01PM Syros Pharmaceuticals (SYRS) Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Sep 13, 2022 04:01PM Syros Receives FDA Orphan Drug Designation for SY-5609 for the Treatment of Pancreatic Cancer
Sep 7, 2022 07:30AM Syros to Present at H.C. Wainwright 24th Annual Global Investment Conference
Sep 2, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 9, 2022 07:30AM Syros Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Aug 4, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 3, 2022 04:03PM Syros Pharmaceuticals (SYRS) Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Aug 3, 2022 04:01PM Syros Receives Positive Opinion on Orphan Drug Designation from the European Medicines Agency for Tamibarotene for the Treatment of MDS
Aug 2, 2022 07:30AM Syros to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022
Jul 5, 2022 07:02AM Syros Pharmaceuticals (SYRS) to Raise Approximately $190 Million Through Merger with TYME Technologies (TYME) and Concurrent Private Placement
Jul 5, 2022 07:00AM Syros to Raise Approximately $190 Million Through Merger with TYME Technologies and Concurrent Private Placement
Jul 1, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 8, 2022 07:30AM Syros to Present at JMP Securities Life Sciences Conference
Jun 3, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 16, 2022 07:30AM Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 9, 2022 07:30AM Syros to Report First Quarter 2022 Financial Results on Monday, May 16, 2022
Apr 29, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 8, 2022 01:00PM Syros Presents New Preclinical Data on its CDK12 Inhibitor Program at American Association for Cancer Research (AACR) Annual Meeting 2022
Apr 1, 2022 04:01PM Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 15, 2022 07:32AM Syros Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Mar 9, 2022 07:30AM Syros to Report Fourth Quarter and Full Year 2021 Financial Results on Tuesday, March 15, 2022
Mar 8, 2022 04:31PM Syros to Present New Preclinical Data on its CDK12 Inhibitor Program at the American Association for Cancer Research (AACR) Annual Meeting 2022
Feb 28, 2022 07:30AM Syros to Participate in Upcoming Virtual Investor Conferences in March
Feb 2, 2022 04:35PM Syros Pharmaceuticals (SYRS) Confirms FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
Feb 2, 2022 04:01PM Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
Jan 10, 2022 07:00AM Syros Announces Clinical Updates and 2022 Goals to Support its Advancement to a Fully Integrated Biopharmaceutical Company
Nov 16, 2021 07:30AM Syros to Participate in Upcoming Investor Conferences
Nov 5, 2021 07:30AM Syros Reports Third Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Oct 29, 2021 07:30AM Syros to Report Third Quarter 2021 Financial Results on Friday, November 5, 2021
Sep 29, 2021 08:00AM Syros Announces First Patient in Dose Confirmation Study of SY-2101, a Novel Oral Form of Arsenic Trioxide, in Acute Promyelocytic Leukemia
Sep 10, 2021 07:34AM Syros Pharmaceuticals (SYRS) Appoints Deborah Dunsire to its Board
Sep 10, 2021 07:30AM Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
Sep 9, 2021 08:00AM Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
Sep 7, 2021 08:00AM Syros to Present at Upcoming Investor Conferences in September
Aug 5, 2021 07:30AM Syros Reports Second Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Aug 5, 2021 07:20AM Syros Pharmaceuticals (SYRS) Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
Aug 5, 2021 07:15AM Syros Announces Agreement with Roche to Evaluate SY-5609 as Part of a Novel Combination for Treatment of Colorectal Cancer
Jul 29, 2021 07:30AM Syros to Report Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Jun 9, 2021 08:01AM Syros Pharmaceuticals to Present at JMP Securities 2021 Life Sciences Conference
May 19, 2021 08:31AM Syros to Host Key Opinion Leader Webcast Series on Targeted Hematology Portfolio
May 6, 2021 07:31AM Syros Reports First Quarter 2021 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Apr 29, 2021 08:01AM Syros to Report First Quarter 2021 Financial Results on Thursday May 6, 2021
Mar 25, 2021 07:09AM IMV Inc. (IMV) Names Kyle Kuvalanka to Board
Mar 25, 2021 07:05AM IMV Appoints Kyle Kuvalanka to Board of Directors
Mar 4, 2021 07:30AM Syros Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Key Accomplishments and Upcoming Milestones
Jan 11, 2021 07:34AM Syros Pharmaceuticals (SYRS) Announces Strategic Priorities and Expected Milestones
Jan 11, 2021 07:30AM Syros Announces Strategic Priorities and Expected Milestones
Jan 7, 2021 08:30AM Syros to Present at 39th Annual J.P. Morgan Healthcare Conference
View More Recent Stories View Older Stories